What Is Melanotan II? Benefits, Research & Safety

Melanotan II was developed in the 1980s at the University of Arizona by researchers led by Dr. Victor Hruby. The initial goal was to create a synthetic melanotropin that could stimulate melanin production and provide protective tanning without UV exposure, potentially reducing skin cancer risk. The research built upon earlier work with Melanotan I (afamelanotide), a linear α-MSH analogue. Melanotan II was designed as a cyclic peptide for improved stability and potency, with modifications to enhance resistance to enzymatic degradation. During Phase I and II clinical trials investigating tanning effects, researchers observed unexpected side effects including spontaneous penile erections and increased sexual arousal in both male and female subjects. These findings led to recognition of the peptide's effects on central melanocortin receptors involved in sexual function. Following these discoveries, research focus split: some work continued on the tanning aspects while pharmaceutical development pivoted toward isolating the sexual function effects. This led to the creation of PT-141 (bremelanotide), a derivative specifically targeting sexual dysfunction. Despite promising research, Melanotan II never completed regulatory approval processes. Concerns about long-term safety, particularly regarding potential effects on existing moles and theoretical melanoma risk, contributed to the decision not to pursue full development for tanning indications. The peptide became widely available through unregulated channels and gained popularity in the tanning community, leading to regulatory warnings and enforcement actions in multiple countries.